Can molecular patterns help to classify overlapping entities in myeloid neoplasms?

被引:1
|
作者
Hoermann, Gregor [1 ]
Khoury, Joseph D. [2 ]
机构
[1] MLL Munich Leukemia Lab, Munich, Germany
[2] Univ Nebraska Med Ctr, Nebraska Med Ctr 985900, Dept Pathol Microbiol & Immunol, Omaha, NE 68198 USA
关键词
chronic myelomonocytic leukaemia; disease classification; genetics; molecular patterns; myelodysplastic neoplasms; myeloid neoplasms; myeloproliferative neoplasms; systemic mastocytosis; EARLY PRIMARY MYELOFIBROSIS; TYROSINE KINASE JAK2; CLONAL HEMATOPOIESIS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; RING SIDEROBLASTS; MYELODYSPLASTIC SYNDROMES; INTEROBSERVER VARIANCE; REFRACTORY-ANEMIA; SETBP1; MUTATIONS;
D O I
10.1111/his.15339
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid neoplasms include myeloproliferative and myelodysplastic neoplasms and acute myeloid leukaemia. Historically, these diseases have been diagnosed based on clinicopathological features with sometimes arbitrary thresholds that have persisted even as molecular features were gradually incorporated into their classification. As such, although current diagnostic approaches can classify the majority of myeloid neoplasms accurately using a combination of molecular and clinicopathological features, some areas of overlap persist and occasionally pose diagnostic challenges. These include overlap across BCR::ABL1-negative myeloproliferative neoplasms; between clonal cytopenia of undetermined significance and myelodysplastic neoplasms; myelodysplastic/myeloproliferative neoplasms; and, detection of KIT mutations in myeloid neoplasms other than mastocytosis, raising the prospect of systemic mastocytosis. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms, and molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. For future development, molecular testing will likely include whole genome and transcriptome sequencing, and primarily molecular classifications of myeloid neoplasms have already been suggested. As such, genetically defined groups should still constitute the basis for our understanding of disease development from early onset to progression, while clinicopathological features could then be used to describe the stage of the disease rather than the specific type of myeloid neoplasm. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms and molecular features have been incorporated into their classification, together with clinicopathological features. Molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. image
引用
收藏
页码:146 / 157
页数:12
相关论文
共 41 条
  • [21] Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations
    Qu, Shiqiang
    Li, Bing
    Qin, Tiejun
    Xu, Zefeng
    Pan, Lijuan
    Hu, Naibo
    Huang, Gang
    Gale, Robert Peter
    Xiao, Zhijian
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (06) : 1006 - 1010
  • [22] How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas
    Clark, Kenneth
    Voronovich, Zoya
    Horbinski, Craig
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 139 (03) : 275 - 288
  • [23] Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms
    Johnson, Steven M.
    Haberberger, James
    Galeotti, Jonathan
    Ramkissoon, Lori
    Coombs, Catherine C.
    Richardson, Daniel R.
    Foster, Matthew C.
    Duncan, Daniel
    Montgomery, Nathan D.
    Ferguson, Naomi L.
    Zeidner, Joshua F.
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 209 - 218
  • [24] The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition
    Kanagal-Shamanna, Rashmi
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (04) : 336 - 344
  • [25] Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
    Spinner, Michael
    Aleshin, Alexey
    Santaguida, Marianne T.
    Schaffert, Steven A.
    Zehnder, James L.
    Patterson, A. Scott
    Gekas, Christos
    Heiser, Diane
    Greenberg, Peter L.
    BLOOD ADVANCES, 2020, 4 (12) : 2768 - 2778
  • [26] Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
    Badar, Talha
    Nanaa, Ahmad
    Foran, James M.
    Viswanatha, David
    Al-Kali, Aref
    Lasho, Terra
    Finke, Christy
    Alkhateeb, Hassan B.
    He, Rong
    Gangat, Naseema
    Shah, Mithun
    Tefferi, Ayalew
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Ongie, Laura J.
    Chlon, Timothy
    Ferrer, Alejandro
    Patnaik, Mrinal M.
    HAEMATOLOGICA, 2023, 108 (11) : 3033 - 3043
  • [27] Imprinting disorders: a group of congenital disorders with overlapping patterns of molecular changes affecting imprinted loci
    Eggermann, Thomas
    de Nanclares, Guiomar Perez
    Maher, Eamonn R.
    Temple, I. Karen
    Tumer, Zeynep
    Monk, David
    Mackay, Deborah J. G.
    Gronskov, Karen
    Riccio, Andrea
    Linglart, Agnes
    Netchine, Irene
    CLINICAL EPIGENETICS, 2015, 7
  • [28] Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study
    Perkins, Geraldine
    Svrcek, Magali
    Bouchet-Doumenq, Cecile
    Voron, Thibault
    Colussi, Orianne
    Debove, Clotilde
    Merabtene, Fatiha
    Dumont, Sylvie
    Sauvanet, Alain
    Hammel, Pascal
    Cros, Jerome
    Andre, Thierry
    Bachet, Jean-Baptiste
    Bardier, Armelle
    Douard, Richard
    Meatchi, Tchao
    Peschaud, Frederique
    Emile, Jean-Francois
    Cojean-Zelek, Isabelle
    Laurent-Puig, Pierre
    Taieb, Julien
    BRITISH JOURNAL OF CANCER, 2019, 120 (07) : 697 - 702
  • [29] Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations
    Tashakori, Mehrnoosh
    Khoury, Joseph D.
    Routbort, Mark J.
    Patel, Keyur P.
    Wang, Sa A.
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Luthra, Rajyalakshmi
    Hu, Shimin
    Lin, Pei
    Bueso-Ramos, Carlos E.
    Medeiros, L. Jeffrey
    Loghavi, Sanam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S340 - S340
  • [30] Molecular monitoring in chronic myeloid leukemia-how low can you go?
    Branford, Susan
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 156 - 163